Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts have given Palisade Bio a consensus rating of "Moderate Buy" from eight brokerages (1 sell, 6 buy, 1 strong buy) with an average 12‑month target price of $10.20.
• Large institutional buying occurred in Q4—Perceptive Advisors ($28.3M), Commodore Capital ($26.9M), Janus Henderson ($24.8M), RA Capital ($16.7M) and Eversept ($12.7M)—and institutions now own about 11.79% of the shares; the stock trades around $1.82 with a market cap of ~$302M and a 12‑month range of $0.53–$2.64.
• Palisade Bio is a clinical‑stage biotech developing localized immunotherapies centered on TLR9 agonist prodrugs, with lead candidate PDS0108 currently in Phase 1/2 trials for advanced solid tumors.

Shares of Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $10.20.

PALI has been the subject of several research analyst reports. Stifel Nicolaus initiated coverage on Palisade Bio in a research report on Wednesday, February 25th. They issued a "buy" rating and a $5.00 price objective for the company. Piper Sandler initiated coverage on Palisade Bio in a research report on Monday, December 29th. They issued an "overweight" rating and a $25.00 price objective for the company. B. Riley Financial initiated coverage on Palisade Bio in a research report on Friday, January 9th. They issued a "buy" rating and a $7.00 price objective for the company. Wolfe Research initiated coverage on Palisade Bio in a research report on Thursday. They issued an "outperform" rating and a $7.00 price objective for the company. Finally, Wall Street Zen upgraded Palisade Bio from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th.

Palisade Bio Price Performance

Palisade Bio stock opened at $1.82 on Friday. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.64. The business has a 50 day simple moving average of $1.81 and a 200-day simple moving average of $1.83. The stock has a market capitalization of $301.90 million, a PE ratio of -0.86 and a beta of 1.36.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Perceptive Advisors LLC purchased a new position in Palisade Bio in the fourth quarter worth $28,318,000. Commodore Capital LP acquired a new stake in Palisade Bio in the fourth quarter valued at $26,896,000. Janus Henderson Group PLC acquired a new stake in Palisade Bio in the fourth quarter valued at $24,822,000. RA Capital Management L.P. acquired a new stake in Palisade Bio in the fourth quarter valued at $16,742,000. Finally, Eversept Partners LP acquired a new stake in Palisade Bio in the fourth quarter valued at $12,670,000. Hedge funds and other institutional investors own 11.79% of the company's stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.